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Gastric carcinogenesis is a multistep process orchestrated by aberrancies in the genetic
s and epigenetic regulation of oncogenes and tumor suppressor genes. Chronic infection
with Helicobacter pylori is the strongest known risk factor for the development of gastric
cancer. H. pylori expresses a spectrum of virulence factors that dysregulate host intracel-
lular signaling pathways that lower the threshold for neoplastic transformation. In addition
to bacterial determinants, numerous host and environmental factors increase the risk of
gastric carcinogenesis. Recent discoveries have shed new light on the involvement of
microRNAs (miRNAs) in gastric carcinogenesis. miRNAs represent an abundant class of
small, non-codingRNAs involved in global post-transcriptional regulation and, consequently,
play an integral role atmultiple steps in carcinogenesis, including cell cycle progression, pro-
liferation, apoptosis, invasion, and metastasis. Expression levels of miRNAs are frequently
altered in malignancies, where they function as either oncogenic miRNAs or tumor sup-
N
pressor miRNAs. This review focuses on miRNAs dysregulated by H. pylori and potential
etiologic roles they play in H. pylori -mediated gastric carcinogenesis.
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INTRODUCTION
Microbial infections are among the most signiﬁcant causes of
cancer worldwide with nearly one in ﬁve malignancies resulting
from infectious agents (Parkin, 2006). Gastrointestinal cancers
represent a major global health concern and account for nearly
20% of all cancer-related deaths (Ferlay et al., 2007). Despite
the decreasing incidence of gastric cancer in developed coun-
tries, it remains the second leading cause of cancer-related death
throughout the world, with ∼700,000 deaths attributed to this
malignancy annually (Parkin et al., 2005). The major contributing
factor to the development of gastric cancer is colonization and
chronic infection by the bacterial pathogen, Helicobacter pylori.
H. pylori selectively colonizes the gastric epithelium of over 50%
of the world’s population and typically persists for the lifetime
of the host. Among colonized individuals, however, only a frac-
tiondevelop gastric adenocarcinoma,emphasizing the importance
of understanding the pathogenic mechanisms by which H. pylori
promotes chronic inﬂammation and the progression to gastric
cancer.
VIRULENCE FACTORS THAT MEDIATE HELICOBACTER
PYLORI PATHOGENESIS
Chronic gastric inﬂammation induced by the bacterial pathogen,
H. pylori, is the strongest known risk factor for the development
of atrophic gastritis, metaplasia, dysplasia, and ultimately gastric
adenocarcinoma (Figure 1). H. pylori is a Gram-negative, helical-
shaped bacterium speciﬁcally adapted to persist within the human
gastric niche. H. pylori possesses numerous elements to success-
fully colonize the gastric mucosa, establish chronic infection, and
induce gastric pathology. In vivo, approximately 20% of H. pylori
adhere to the gastric epithelium (Hessey et al., 1990). The large
repertoire of adhesins expressed by H. pylori likely contribute
to its speciﬁc adaptation to the gastric niche, allowing ﬂexibil-
ity to target speciﬁc host cells and to exert a dynamic range of
effector functions on host cells. H. pylori expresses a number of
adhesins that have been linked to virulence. SabA (sialic acid-
binding adhesin), which binds host sialyl-Lewisx, contributes to
H. pylori persistence and mediates chronic gastric inﬂammation
and injury (Mahdavi et al., 2002). The presence of blood group
antigen-binding adhesin (BabA), which binds the host Lewisb
blood group antigen, increases the risk of gastric cancer in a syn-
ergistic fashion with other virulence factors, such as CagA (Ilver
et al., 1998; Gerhard et al., 1999).
Following adherence and colonization of the gastric mucosa,
H. pylori induces chronic gastritis and gastric injury, which are
characterized by both neutrophilic and lymphocytic inﬂammation
(Marshall et al., 1985; Goodwin et al., 1986). H. pylori expresses
a number of factors capable of modulating the host immune sys-
tem and eliciting proinﬂammatory immune responses. Some of
these virulence factors include vacuolating cytotoxin (VacA) and
the cag (cytotoxin associated gene) pathogenicity island. VacA is
coded by the gene vacA, which is present in all strains of H. pylori,
and which exhibits vacuolating activity (Leunk et al., 1988; Cover
and Blaser, 1992; Cover et al., 1994; Phadnis et al., 1994; Schmitt
andHaas, 1994; Telford et al., 1994). Additionally,VacA can induce
apoptosis of host cells (Kuck et al., 2001; Xia and Talley, 2001) and
suppress proliferation of T and B lymphocytes (Boncristiano et al.,
2003; Gebert et al., 2003; Sundrud et al., 2004), which may con-
tribute to the persistence of H. pylori through dysregulation of the
host immune response. The cag pathogenicity island is present in
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FIGURE 1 | Progression to gastric adenocarcinoma. H. pylori colonizes
the human gastric mucosa and causes superﬁcial gastritis and chronic
inﬂammation over weeks to months. H. pylori expressing key virulence
factors, such as the cag type 4 secretion system (T4SS), and host genetic
polymorphisms in IL-1β,TNFα, and IL-8 promoters that promote high
expression of proinﬂammatory cytokines, augment the risk for developing
atrophic gastritis, intestinal metaplasia, dysplasia, and ultimately, gastric
adenocarcinoma.
∼60%of allH. pylori strains and its presence is strongly associated
with an increased risk of severe gastritis, ulcer disease, and gastric
cancer (Censini et al., 1996; Tomb et al., 1997; Akopyants et al.,
1998; Alm et al., 1999). The cag island encodes a type 4 secretion
system (T4SS), which injects effector molecules, such as CagA,
into host cells. CagA is a 120- to 140-kD protein that contains a
number of tyrosine phosphorylation motifs (Covacci et al., 1993;
Tummuru et al., 1993). Following its injection into host cells,CagA
exerts a wide range of phosphorylation-dependent and indepen-
dent effects, such as cytoskeletal rearrangements, disruption of
cell polarity, and mitogenic and proinﬂammatory responses (Polk
and Peek, 2010). Cumulatively, these bacterial factors contribute to
adherence, persistence, host immune modulation, and virulence
of H. pylori within the gastric niche, ultimately resulting in H.
pylori-mediated chronic inﬂammation and a series of pathological
outcomes that facilitate the development of gastric cancer.
HOST FACTORS THAT CONTRIBUTE TO GASTRIC
CARCINOGENESIS
In addition to microbial factors that potentiate gastric disease,
there are a number of host factors that contribute to chronic
gastritis and the progression to gastric adenocarcinoma.Cyclooxy-
genases (COX) are key enzymes that catalyze prostaglandin syn-
thesis. Of the three isoforms identiﬁed, COX-2 is upregulated in
gastric epithelial cells upon co-culture with H. pylori (Romano
et al., 1998; Juttner et al., 2003; Meyer et al., 2003; Wu et al.,
2005) and within the gastric mucosa of H. pylori-infected indi-
viduals (Sawaoka et al., 1998; Fu et al., 1999; McCarthy et al.,
1999). In vivo studies show that COX-2 is further upregulated in
H. pylori-mediated adenocarcinoma (Ristimaki et al., 1997; Sung
et al., 2000). COX-2 expression levels are considered an indepen-
dent factor for poor prognosis and correlate with reduced patient
survival, suggesting that H. pylori-induced COX-2 overexpression
is a risk factor for the development of gastric cancer.
Other host factors that increase the propensity for chronic
inﬂammation and gastric adenocarcinoma are polymorphisms
within human IL-1β (interleukin-1), TNF-α (tumor necrosis fac-
tor), and IL-8 promoters (El-Omar et al., 2000, 2003; Machado
et al., 2001; Furuta et al., 2002), which lead to increased expres-
sion of the proinﬂammatory cytokines IL-1β, TNF-α, and IL-8
(Figure 1). These polymorphisms in combination with H. pylori
virulent genotypes increase the risk of gastric cancer up to 87-fold
over baseline (Figueiredo et al., 2002), emphasizing the impor-
tance of microbial–host interactions in the development of gastric
cancer. Collectively, data demonstrate that H. pylori virulence fac-
tors, host genetics, and environmental factors interact to induce
and maintain the persistent inﬂammatory immune response that
initiates the multistep process leading to gastric cancer.
microRNAs
Recent discoveries have shed new light on the involvement of
host microRNAs (miRNAs) in gastric carcinogenesis. miRNAs
are small, non-coding RNAs∼20–25 nucleotides in length, which
function as critical post-transcriptional regulators of gene expres-
sion (Bartel, 2009). miRNAs were ﬁrst characterized in 1993 (Lee
et al., 1993),but their distinct role in transcriptional regulationwas
not recognized until the early 2000s. Most miRNAs are found in
intergenic regions and contain their own promoter and regulatory
units. Processed miRNAs function by binding to the 3′ untrans-
lated region (3′UTR) of messenger RNAs (mRNAs), typically
resulting in mRNA degradation and gene silencing or transla-
tional repression (Bartel, 2009). It is estimated that the human
genome encodes thousands of miRNAs, targeting∼30–60% of all
protein-coding genes (Lewis et al., 2003). miRNAs are involved in
many biological processes, including development, differentiation,
angiogenesis, cell cycle progression, proliferation, apoptosis, and
signal transduction pathways (Ambros, 2004). Dysregulation of
miRNA expression with subsequent disruption of these biological
processes can result in disease states. There is an increasing body
of evidence regarding the regulatory roles of miRNAs in immune
and inﬂammatory disorders (Wu et al., 2008; Sonkoly and Pivarcsi,
2009), and aberrant expression of miRNAs is observed in many
cancers (Lu et al., 2005; Volinia et al., 2006). Thus, recent studies
have begun to dissect the mechanisms by which miRNAs function
as either oncogenic miRNAs (oncomiRs) or tumor suppressors to
promote or prevent tumorigenesis.
DYSREGULATION OF miRNAs IN H. PYLORI -INDUCED
GASTRIC CARCINOGENESIS
The number of studies analyzing miRNA expression proﬁles in
gastric cancer is rapidly increasing and a comprehensive list of
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miRNAs dysregulated in gastric cancer, conﬁrmed mRNA targets,
and the biological processes affected is shown in Tables A1 and A2
in theAppendix. The ﬁrst study to addressmiRNA expression pro-
ﬁles in various cancers, including gastric cancer, was performed in
2005 (Lu et al., 2005). Subsequent studies have not only focused
onmiRNA expression proﬁles in gastric cancer, but also those that
are altered in response to H. pylori.
Matsushima et al. (2011) conducted a study to characterize
miRNA expression signatures in H. pylori-infected human gas-
tric mucosa. Using high throughput proﬁling analysis, 31 miR-
NAs were identiﬁed as being differentially expressed between H.
pylori-infected and H. pylori-uninfected gastric mucosa. The rela-
tionship between miRNA expression levels and H. pylori-induced
acute inﬂammation, characterized by neutrophil inﬁltration, and
chronic inﬂammation, characterized by mononuclear cell inﬁl-
tration were also determined. Expression levels of many miRNAs
correlated with either the degree of acute or chronic inﬂamma-
tion and in some cases both (Tables 1 and 2). The relationship
between miRNA expression and extent of glandular atrophy, and
intestinal metaplasia was also assessed, but no signiﬁcant cor-
relations were found (Matsushima et al., 2011). A comprehen-
sive list of miRNAs dysregulated by H. pylori, conﬁrmed mRNA
targets, and biological processes affected is shown in Tables 1
and 2. These data suggest that H. pylori infection affects global
miRNA expression in human gastric mucosa, and this effect is,
in part, linked to H. pylori-induced host inﬂammatory immune
responses.
miRNAs that are dysregulated in response to H. pylori infec-
tion may not be the same miRNAs that are dysregulated in later
stages of gastric disease. A comprehensive review of the literature,
however, revealed that there is a select subset of miRNAs dysregu-
lated both following H. pylori infection as well asin gastric cancer.
These include downregulated miRNAs, let-7a, miR-31, miR-101,
miR-141, miR-203, miR-210, miR-218, miR-375, and miR-449 as
well as upregulatedmiRNAs,miR-17,miR-20a,miR-21,miR-146a,
miR-155, and miR-223. These miRNAs may be more biologically
relevant to H. pylori-induced gastric inﬂammation and carcino-
genesis and represent fruitful targets for studies focused on cancer
that develops in the context of H. pylori infection.
The next sections will discuss miRNA dysregulation in H.
pylori-induced disease and how speciﬁc miRNAs control vari-
ous biological processes related to (1) host inﬂammatory immune
response, (2) cell cycle progression, and (3) apoptosis and
proliferation.
HELICOBACTER PYLORI -INDUCED miRNA DYSREGULATION
TO CONTROL HOST INFLAMMATORY RESPONSES
Host cells recognize invading pathogens and/or pathogen-
associated molecular patterns (PAMPs) through membrane-
associated or cytoplasmic pathogen recognition molecules known
as Toll-like receptors (TLRs) and Nod-like receptors (NLRs),
respectively. PAMPs activate adaptor proteins and transcription
factors that mediate host innate immunity through activation of
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B
cells) signaling (Figure 2).Gastric epithelial cells are the initial host
element encountered by H. pylori. The innate immune response
induced in epithelial cells is characterized by NOD1-dependent
activation of NF-κB in response toH. pylori peptidoglycan (PGN),
which is injected into host cells via the cag T4SS (Viala et al., 2004).
Activation of NF-κB by H. pylori leads to induction of the proin-
ﬂammatory cytokine IL-8 and likely contributes to carcinogenesis
through activation of downstream targets that mediate inﬂamma-
tion, cell cycle progression, proliferation, and apoptosis. Myeloid
cells constitute a second line of defense and secrete proinﬂamma-
tory cytokines such as IL-6, IL-1, and TNF-α to establish T and B
lymphocyte-mediated adaptive immunity.
The involvement of miRNAs in modulating both the innate
and adaptive immune responses is well established (Chen et al.,
2004) and H. pylori can dysregulate miRNA expression to evade
host defenses and successfully persist in the gastric niche. miR-
146a and miR-155 are speciﬁcally involved in H. pylori-induced
negative regulation of the proinﬂammatory immune response
(Figure 2). Changes in miR-146a expression occur in the devel-
opment of gastric cancer and in the negative regulation of the
innate inﬂammatory immune response. Single-nucleotide poly-
morphisms (SNPs) in miR-146a are associated with an increased
susceptibility to gastric cancer (Okubo et al., 2010) and H.
pylori upregulates miR-146a in vitro and in vivo in a CagA-
independent and an NF-κB-dependent manner (Liu et al., 2010;
Li et al., 2011a). miR-146a targets the TLR-signaling adaptor
molecules IRAK1 (interleukin-1 receptor-associated kinase) and
TRAF6 (TNF receptor-associated factor), resulting in negative
regulation of TLR and downstream proinﬂammatory signaling
(Figure 2; Liu et al., 2010; Li et al., 2011a). As a result, miR-146a
overexpression negatively regulates H. pylori-induced IL-8, TNF-
α, IL-1β, GRO-α [CXCL1, chemokine (C-X-C motif) ligand], and
MIP-3α (macrophage inﬂammatory protein) expression, all key
components to the proinﬂammatory innate and adaptive immune
responses (Liu et al., 2010; Li et al., 2011a).
The second miRNA involved in H. pylori-induced downregu-
lation of the host inﬂammatory immune response,miR-155, plays
a critical role in regulating lymphocyte homeostasis and tolerance
(Thai et al., 2007). miR-155 is increased in many malignancies
of B cell or myeloid origin (Volinia et al., 2006). In transgenic
murine models of miR-155 overexpression, mice develop spon-
taneous B cell lymphomas (Costinean et al., 2006). miR-155 is
induced during both bacterial and viral infections in myeloid cells
through activation of TLR-signaling pathways. H. pylori upreg-
ulates miR-155 expression in vitro and in vivo, which occurs in
an NF-κB-dependent manner, and ultimately results in decreased
induction of the proinﬂammatory cytokines, IL-8, and GRO-α
(Xiao et al., 2009b; Tang et al., 2010). miR-155 targets MyD88
(myeloid differentiation primary response gene), the universal
adapter protein used by TLRs to activate NF-κB (Figure 2; Xiao
et al., 2009b; Tang et al., 2010). Decreased levels of MyD88 subse-
quently result in decreasedNF-κBactivation anddampeningof the
host inﬂammatory response (Xiao et al., 2009b; Tang et al., 2010).
Therefore, these data demonstrate that H. pylori dysregulates host
miRNA expression to manipulate the host inﬂammatory immune
response, which may promote bacterial survival and persistence
within the gastricmucosa. Because thesemiRNAs have established
roles in carcinogenesis as well as innate immunity, they could serve
as an important link betweenH. pylori-induced inﬂammation and
carcinogenesis.
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Table 1 | miRNAs downregulated in response to H. pylori.
miRNAs Target mRNAs Biological process targeted Reference
let-7a+ RAB40C Cell cycle progression Matsushima et al. (2011), Motoyama et al. (2008), Yang et al. (2011)
Proliferation
HMGA2 Invasion
let-7b* HMGA2 Invasion Matsushima et al. (2011), Motoyama et al. (2008)
let-7d HMGA2 Invasion Matsushima et al. (2011), Motoyama et al. (2008)
let-7e HMGA2 Invasion Matsushima et al. (2011), Motoyama et al. (2008)
let-7f HMGA2 Invasion Matsushima et al. (2011), Motoyama et al. (2008)
miR-1 ND Proliferation Saito et al. (2011)
miR-31+ ND ND Matsushima et al. (2011)
miR-32 ND ND Matsushima et al. (2011)
miR-34b ND ND Suzuki et al. (2010)
miR-34c ND ND Suzuki et al. (2010)
miR-101 COX-2, FOS Proliferation Matsushima et al. (2011),Varambally et al. (2008),Wang et al. (2010)
MCL1 Apoptosis
EZH2 Invasion migration
miR-103# ND ND Matsushima et al. (2011)
miR-106b p21 Cell cycle progression Kan et al. (2009), Matsushima et al. (2011), Petrocca et al. (2008)
Proliferation
BIM Apoptosis
miR-125a ERBB2 Proliferation Matsushima et al. (2011), Nishida et al. (2011)
miR-130a ND ND Matsushima et al. (2011)
miR-133 ND Proliferation Saito et al. (2011)
miR-141# FGFR2 Proliferation Du et al. (2009), Matsushima et al. (2011)
miR-200a+ ZEB1, ZEB2 Epithelial to mesenchymal transition (EMT) Ahn et al. (2011), Matsushima et al. (2011), Shinozaki et al. (2010)
miR-200b+ BCL2, XIAP Apoptosis Ahn et al. (2011), Matsushima et al. (2011), Shinozaki et al. (2010),
Zhu et al. (2011a)ZEB1, ZEB2 EMT
miR-200c+ BCL2, XIAP Apoptosis Matsushima et al. (2011), Shinozaki et al. (2010), Zhu et al. (2011a)
EMT
miR-203 ABL1 Proliferation Craig et al. (2011b), Matsushima et al. (2011)
Invasion
miR-204 EZR Proliferation Lam et al. (2011), Matsushima et al. (2011)
miR-210 ND ND Matsushima et al. (2011)
miR-214 ND ND Matsushima et al. (2011)
miR-218 ECOP Proliferation Gao et al. (2010), Tie et al. (2010)
Apoptosis
ROBO1 Invasion and metastasis
miR-320+ ND ND Matsushima et al. (2011)
miR-372 LATS2 Cell cycle progression Belair et al. (2011)
miR-373 LATS2 Cell cycle progression Belair et al. (2011)
miR-375+ PDK1, 14-3-3 Apoptosis Ding et al. (2010), Matsushima et al. (2011), Tsukamoto et al. (2010)
JAK2 Proliferation
miR-377 ND ND Matsushima et al. (2011)
miR-379 ND ND Matsushima et al. (2011)
miR-429+ BCL2, XIAP Apoptosis Matsushima et al. (2011), Sun et al. (2011), Zhu et al. (2011a)
MYC Proliferation
miR-449 GMNN, CCNE2 Cell cycle progression Bou Kheir et al. (2011), Lize et al. (2011)
MET, SIRT1 Proliferation
miR-455 ND ND Matsushima et al. (2011)
miR-491-5p ND ND Matsushima et al. (2011)
miR-500 ND ND Matsushima et al. (2011)
(Continued)
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Table 1 | Continued
miRNAs Target mRNAs Biological process targeted Reference
miR-532# ND ND Matsushima et al. (2011)
miR-652# ND ND Matsushima et al. (2011)
Target criteria included (1) reduced protein expression upon miRNA transfection in gastric cells or expression inversely correlated with miRNA in gastric tissue or (2)
presence of miRNA binding site on the 3′UTR of target mRNA conﬁrmed by luciferase reporter assay. ND, target mRNA or biological process not determined. *,
miRNA expression correlates with acute inﬂammation. #, miRNA expression correlates with chronic inﬂammation. +, miRNA expression correlates with both acute
and chronic inﬂammation. Bold indicates miRNA also downregulated in gastric cancer.
Table 2 | miRNAs upregulated in response to H. pylori infection.
miRNAs Target mRNAs Biological process targeted Reference
miR-17∧ p21 Cell cycle progression Saito et al. (2010)
miR-20a∧ p21 Cell cycle progression Saito et al. (2010)
miR-21 PDCD4 Proliferation Zhang et al. (2008)
RECK Apoptosis
PTEN Invasion
miR-146a IRAK1,TRAF6 Immune response Li et al. (2011a), Liu et al. (2010), Xiao et al. (2011)
Proliferation
SMAD4 Apoptosis
miR-155 IKK-ε, SMAD2 Immune response Fassi Fehri et al. (2010), Oertli et al. (2011), Tang et al. (2010), Xiao et al. (2009b)
FADD, PKIα Apoptosis
miR-223* EPB41L3 Invasion and metastasis Li et al. (2011b), Matsushima et al. (2011)
Target criteria included (1) reduced protein expression upon miRNA transfection in gastric cells or expression inversely correlated with miRNA in gastric tissue or (2)
presence of miRNA binding site on the 3′UTR of target mRNA conﬁrmed by luciferase reporter assay. ND, target mRNA or biological process not determined. ∧,
miRNA expression induced by CagA overexpression, not H. pylori infection (Saito et al., 2010). *, miRNA expression correlates with acute inﬂammation. Bold indicates
miRNA also upregulated in gastric cancer.
HELICOBACTER PYLORI AND miRNAS REGULATE CELL
CYCLE PROGRESSION
Disruption of cell cycle progression and increased cellular pro-
liferation are common features of malignancies. Cell cycle pro-
gression requires coordinated expression of cyclins, which results
in sequential activation of cyclin-dependent kinases (CDKs).
miRNA dysregulation promotes cell cycle progression by upreg-
ulating cyclin expression and/or downregulating expression of
CDK inhibitors (p15, p16, p18, p19, p21, p27, p28, p57) in var-
ious cancers, including gastric cancer (Figure 3). miR-449, a
miRNA downregulated in H. pylori-infected gastric tissue and
in gastric cancer, targets GMNN (geminin) and CCNE2 (cyclin
E2; Figure 3). Both geminin and cyclin E2 are overexpressed in
numerous malignancies and promote M/G1 and G1/Scell cycle
progression and cell proliferation (Bou Kheir et al., 2011; Lize
et al., 2011). Consequently, downregulation of miR-449, as occurs
following H. pylori infection, promotes cell cycle progression and
proliferation through upregulation of geminin and cyclin E2.
p42.3, a recently identiﬁed protein signiﬁcantly upregulated in
gastric cancer, regulates G2/M cell cycle progression and prolifer-
ation in gastric cancer cells (Xu et al., 2007). miR-29a, a miRNA
signiﬁcantly downregulated in gastric cancer, targets p42.3 (Cui
et al., 2011;Figure 3). Thus, the downregulation ofmiR-29a results
in a reciprocal increase in p42.3 expression, promoting increased
cell cycle progression and proliferation.
The retinoblastoma protein (RB1) is a tumor suppressor dys-
regulated in many cancers. RB1 functions to prevent excessive cell
proliferation by inhibiting G1/S cell cycle progression. RB1 binds
and inhibits transcription factors of the E2F family. When RB1
is bound to E2F the complex acts as a growth suppressor and
prevents progression through cell cycle. A number of miRNAs tar-
get these factors. For instance, miR-106a is upregulated in gastric
cancer and targets RB1 (Volinia et al., 2006), while miR-331-3p is
downregulated in gastric cancer and targets E2F1 (Guo et al., 2010;
Figure 3).
TGFβ suppresses gastric cancer cell proliferation via the tran-
scriptional upregulation of the CDK inhibitor, p21 (Yoo et al.,
1999). miR-93 and miR-106b directly target p21, resulting in
its transcriptional silencing and impairment of the tumor-
suppressing activity of TGFβ (Petrocca et al., 2008; Kan et al.,
2009; Figure 3). In addition, miR-25 targets the CDK inhibitor,
p57, while miR-221 and miR-222 target the CDK inhibitors, p27
and p57 (Kimet al., 2009;Figure 3). These oncogenicmiRNAclus-
ters are also signiﬁcantly upregulated in gastric cancer (Volinia
et al., 2006; Petrocca et al., 2008; Guo et al., 2009; Kim et al.,
2009; Yao et al., 2009). Overexpression of most of these miRNAs
results in activation of CDK2, thereby promoting G1/S phase pro-
gression. Since numerous reports have described the role of H.
pylori in the modulation of cyclins, CDKs, and CDK inhibitors
and their link to gastric carcinogenesis (Shirin et al., 2001), these
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FIGURE 2 |TLR, NOD, and the NF-κB signaling pathways. Host cells
recognize invading pathogens through extracellular Toll-like receptors (TLRs)
and intracellular Nod-like receptors (NOD). Pathogens, such as H. pylori,
activateTLRs and adaptor molecules that ultimately lead to NF-κB activation
and a proinﬂammatory immune response. The key adaptor molecule
responsible for signaling byTLRs is MyD88. MyD88 and other adaptor
proteins (IRAK-1 andTRAF6) in this signaling cascade are targeted by
miRNAs to dampen the host immune response.
data suggest that H. pylori modulates expression of cyclins, CDKs,
andCDK inhibitors through dysregulation of hostmiRNAs,which
may increase the propensity for gastric transformation.
HELICOBACTER PYLORI AND miRNA DYSREGULATION
INHIBIT APOPTOSIS AND PROMOTE CELL SURVIVAL
Increased cellular proliferation and evasion of apoptosis are hall-
marks of cellular transformation. Apoptosis can be classiﬁed as
being dependent on either the intrinsic or extrinsic pathways. The
intrinsic pathway is initiatedwithin cells and hinges on the balance
of activity between pro-apoptotic and anti-apoptotic members
of the Bcl-2 (B cell lymphoma 2) superfamily of proteins, which
FIGURE 3 | Regulation of cell cycle progression.The cell cycle consists
of four distinct phases: G1, S, G2, and M.Two key classes of regulatory
molecules, cyclins and cyclin-dependent kinases (CDKs), determine a cells
progress through the cell cycle. CDK inhibitors prevent the progression of
cell cycle and function as tumor suppressors. miRNAs target the key
regulatory molecules, cyclins and CDKs, as well as CDK inhibitors to disrupt
normal cell cycle progression.
act to regulate the permeability of the mitochondrial membrane.
miRNAs regulate apoptosis by altering expression and balance of
members of the pro-apoptotic (e.g., Bax, Bak, Bim, Bad, Bid, and
BNIP3L) and anti-apoptotic (e.g., Bcl-2, Bcl-xL, and Mcl-1) Bcl-2
protein family (Figure 4).
Numerous miRNAs overexpressed in gastric cancer function
as oncomiRs by targeting members of the pro-apoptotic Bcl-2
protein family. In addition to their role in regulating cell cycle
progression, miR-25, miR-93, and miR-106b also inhibit apopto-
sis by preventing expression of the pro-apoptotic protein, Bim
(Kan et al., 2009; Figure 4). Overexpression of miR-130b also con-
tributes to suppression of Bim and apoptosis by targeting RUNX3
(runt-related transcription factor; Lai et al., 2010), a known tumor
suppressor frequently silenced in gastric cancer (Li et al., 2002).
miR-150 targets the EGR2 (early growth response protein; Wu
et al., 2010), a tumor-suppressive transcription factor that induces
apoptosis by direct transactivation of pro-apoptotic factors, Bak,
and BNIP3L (Unoki and Nakamura, 2003).
Numerous tumor suppressor miRNAs target members of the
anti-apoptotic Bcl-2 protein family and are consequently down-
regulated in gastric cancer. miR-15b, miR-16, miR-34, miR-181b,
miR-181c, and miR-497 directly target anti-apoptotic BCL2 (Ji
et al., 2008; Xia et al., 2008; Zhu et al., 2010b, 2011b; Figure 4).
These miRNA clusters are downregulated in gastric cancer cells
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FIGURE 4 | Signaling cascades that regulate the intrinsic and extrinsic
pathways of apoptosis.TNFα signaling leads to activation of NF-κB and the
anti-apoptotic protein XIAP. Other receptors that detect survival factors, such
as growth factors and cytokines, induce ERK1/2 and PI3K/Akt signaling
cascades that ultimately result in the inhibition of the pro-apoptotic protein,
Bad. In contrast, upon removal of survival factors, these receptors can signal
via JNK to induce the pro-apoptotic protein, Bax. Pro-apoptotic and
anti-apoptotic proteins govern the intrinsic pathway of cell death, which
results in the release of cytochrome c from the mitochondria and induction of
the caspase cascade. Signaling through death receptors initiate the extrinsic
pathway of apoptosis, leading to the induction of caspases and cell death.
There are numerous miRNAs that regulate each of these pathways and
dysregulation of these miRNAs can lead to anti-apoptotic and tumorigenic
responses.
(Guo et al., 2009), leading to increased expression of Bcl-2 and
inhibition of apoptosis. The miR-200bc/429 cluster is downreg-
ulated in gastric cells, and these miRNAs directly target BCL2
and XIAP (x-linked inhibitor of apoptosis), leading to reduced
expression and increased apoptosis (Zhu et al., 2011a; Figure 4).
miR-101 and miR-512-5p target another anti-apoptotic member
of the Bcl-2 family, MCL1 (myeloid leukemia cell differentiation
protein; Saito et al., 2009; Wang et al., 2010; Figure 4). Both miR-
101 and miR-512-5p are downregulated in gastric cancer, leading
to increased levels of Mcl-1 and an anti-apoptotic phenotype. In
addition, miR-101 is downregulated by H. pylori (Matsushima
et al., 2011). miR-449 is also likely involved inmediating the intrin-
sic pathway of apoptosis and has been classiﬁed as a potent inducer
of cell cycle arrest and cell death.miR-449 expression is reduced in
H. pylori-infected gastric tissue, and its expression is lost in gastric
tumors (Bou Kheir et al., 2011; Lize et al., 2011). Conversely, over-
expression of miR-449 inhibits cellular proliferation and induces
signiﬁcant levels of apoptosis, and since miR-449 belongs to the
family of p53-responsive miRNAs, its overexpression also results
in activation of p53 and apoptosis-speciﬁc marker, caspase 3.
In contrast to the intrinsic pathway, the extrinsic pathway of
apoptosis is initiated on the cell surface through the activation of
speciﬁc pro-apoptotic, death receptors. Speciﬁc pro-apoptotic lig-
ands are known to activate the extrinsic pathway of apoptosis via
speciﬁc receptor binding. Ligand binding induces receptor clus-
tering and the recruitment of the adaptor protein Fas-associated
death domain (FADD), leading to induction of caspases and ulti-
mately cell death. In addition to its role in regulating the host
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immune response, miR-155 targets FADD (Figure 4), leading to
decreased expression of this key adaptor molecule (Xiao et al.,
2009b). Therefore, the upregulation of miR-155 by H. pylori and
during carcinogenesis results in downregulation of FADD and
inhibition of apoptosis.
In addition to targeting proteins directly involved in the intrin-
sic and extrinsic pathways of cell death, miRNAs target other
factors that ultimately lead to inhibition of apoptosis and increased
proliferation. miR-375 targets 14-3-3 zeta, an anti-apoptotic pro-
tein that mediates cell survival by binding the pro-apoptotic
protein Bad and sequestering it to the cytosol (Tsukamoto et al.,
2010; Figure 4). miR-375 also targets PDK1 (3-phosphoinositide
dependent protein kinase), a kinase that directly phosphorylates
Akt, thereby regulating the PI3K/Akt signaling pathway (Figure 4).
Overexpression of miR-375 was shown to substantially reduce cell
viability through induction of the caspase-dependent apoptotic
pathway. miR-375 is one of the most highly downregulated miR-
NAs in gastric cancer (Tsukamoto et al., 2010), suggesting its role
as a potent tumor suppressor that contributes to the development
of gastric carcinoma.
In contrast,miR-21, a known oncomir that targetsmany known
tumor suppressors, is consistently upregulated in various human
cancers, including gastric cancer (Volinia et al., 2006; Chan et al.,
2008; Petrocca et al., 2008; Zhang et al., 2008; Guo et al., 2009),
and miR-21 expression is increased in H. pylori-infected gastric
tissues (Zhang et al., 2008). Overexpression of miR-21 shifts the
balance between proliferation and apoptosis, increasing cellular
proliferation and inhibiting apoptosis. Speciﬁcally,miR-21 targets
PTEN (phosphatase and tensin homolog), a tumor suppressor and
negative regulator of the PI3K/Akt signaling pathway (Yamanaka
et al., 2009), which is involved in both apoptotic and proliferative
pathways (Figure 4).Mutations inPTEN are important in the pro-
gression of many cancers, including gastric carcinoma (Kang et al.,
2002). miR-21 likely also contributes to apoptosis by targeting
PDCD4 (programmed cell death protein 4), which is localized to
the nucleus of proliferating cells; however, its direct role in apopto-
sis has not been elucidated (Lu et al., 2008;Motoyama et al., 2010).
Similar to PI3K/Akt signaling, the NF-κB signaling pathway is
important in inhibition of apoptosis and cell survival. The NF-κB
signaling cascade is activated during H. pylori-induced gastritis
and is constitutively active in gastric cancer (Sasaki et al., 2001).
miR-218 expression is reduced in numerous cancers, including
gastric cancer. H. pylori infection also reduces the expression of
miR-218 in vitro and in vivo. miR-218 induces apoptosis in gas-
tric cancer cells through direct targeting of ECOP (epidermal
growth factor receptor-co-ampliﬁed and overexpressed protein), a
knownpositive regulator of NF-κB transcriptional activity. Down-
regulation of miR-218 leads to overexpression of ECOP, inhibi-
tion of NF-κB transcriptional activation, and transcription of a
downstream target COX-2, ultimately inhibiting apoptosis, and
inducing cell proliferation (Gao et al., 2010). Another miRNA
important in regulating NF-κB signal transduction pathways is
miR-9, which directly targets NF-κB1, thereby suppressing NF-
κB transcriptional activity (Figure 4). miR-9 is downregulated in
gastric cancer and in vitro studies have shown that restoration of
miR-9 expression suppresses proliferation of gastric cancer cells
(Luo et al., 2009; Wan et al., 2010). Cumulatively, these studies
demonstrate that aberrant activation of NF-κB signaling as a result
of H. pylori-inducedmiRNA dysregulation results in inhibition of
apoptosis and increased proliferation, thereby sensitizing cells for
subsequent mutagenesis.
miR-451, another downregulated miRNA in H. pylori-infected
gastric mucosa and gastric cancer, targets MIF (macrophage
migration inhibitory factor; Bandres et al., 2009), a lymphokine
involved in cell-mediated immunity that is expressed in response
to H. pylori infection and during gastric carcinogenesis (He et al.,
2006). Overexpression of miR-451 results in targeted downregu-
lation of MIF, which is accompanied by a decrease in cell pro-
liferation and increased apoptosis (Figure 4). Furthermore, there
is an inverse correlation between miR-451 and MIF expression
in gastric cancer, suggesting that miR-451 functions as a tumor
suppressor by silencing MIF expression, leading to a prolifera-
tive and anti-apoptotic phenotype (Bandres et al., 2009).miR-141,
another miRNA signiﬁcantly decreased in H. pylori-infected gas-
tric tissue (Matsushima et al., 2011) as well as gastric carcinoma,
targets FGFR2 (ﬁbroblast growth factor receptor), and overex-
pression of miR-141 leads to decreased FGFR2 expression and
inhibition of proliferation (Du et al., 2009; Figure 4). miR-23a
functions as a growth-promoting and anti-apoptotic factor. It is
signiﬁcantly upregulated in gastric adenocarcinoma and targets
IL-6R (interleukin-6 receptor), which promotes increased prolif-
eration and decreased apoptosis in gastric adenocarcinoma cells
(Zhu et al., 2010a; Figure 4).
HELICOBACTER PYLORI AND miRNA DYSREGULATION
PROMOTES CELL INVASION AND METASTASIS
Invasion andmetastasis are hallmarks of cancer cells. Several intra-
cellular signaling pathways, such as those mediated by TGFβ and
hepatocyte growth factor/Met signaling, promote metastasis. In
addition to its role in regulating cell cycle progression, theH. pylori
downregulatedmiR-449 also targetsMet, a knownproto-oncogene
that encodes the hepatocyte growth factor receptor. Aberrant acti-
vation of Met triggers oncogenic processes, such as proliferation,
angiogenesis, invasion, andmetastasis (Bou Kheir et al., 2011; Lize
et al., 2011). Thus, the targeted downregulation of miR-449 by H.
pylori and during gastric carcinogenesis results in upregulation
of Met, increased cell proliferation, and likely other oncogenic
processes.
The metastatic potential of cancer cells is also regulated by
mechanisms that control cell survival, cytoskeletal changes, as
well as the activity of extracellular matrix-degrading proteinases
(MMPs). Many miRNAs known to regulate cell cycle progression,
proliferation, and apoptosis pathways are also involved in metas-
tasis. For example, overexpression of miR-21 has been shown to
increase the invasiveness of gastric cancer cells. In addition to
its known tumor suppressor targets, miR-21 also targets RECK
(reversion-inducing-cysteine-rich protein with kazal motifs), a
tumor and metastasis suppressor that inhibits tumor metasta-
sis and angiogenesis through modulation of matrix metallopro-
teinases (MMPs; Zhang et al., 2008). H. pylori induces expression
of MMPs, including MMP-1, MMP-2, MMP-3, MMP-7, MMP-9,
which have been linked to H. pylori-induced disease and car-
cinogenesis (Elkington et al., 2005). These data suggest that H.
pylori has the potential to modulate expression of MMPs through
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dysregulation of host miRNAs and these disruptions may increase
the propensity for gastric transformation.
miR-106a is signiﬁcantly upregulated in cancer cells (Volinia
et al., 2006) and is known to correlate with increased lymphatic
and distant metastasis (Xiao et al., 2009a). Conversely, miR-218,
a tumor suppressor miRNA, is downregulated in gastric cancer
(Volinia et al., 2006), which correlates with increased metastasis
and invasion. This is thought to occur through direct target-
ing of ROBO1 (roundabout homolog), which leads to enhanced
signaling through the ROBO1 receptor. The SLIT/ROBO signal-
ing pathway has been implicated in many biological responses
through regulation of cell migration (Tie et al., 2010). Thus, dis-
ruption of this signaling cascade can result in increased invasion
and metastasis.
CONCLUSION
The discovery of miRNAs just over a decade ago has challenged
the central dogma of genetic and epigenetic regulation. Although
extensive work has been dedicated to identifying miRNAs, mRNA
targets, and their contribution to accepted regulatory networks,we
have only begun to scratch the surface. With thousands of miR-
NAs within the human genome, and the ability of each miRNA
to target and regulate numerous protein-coding mRNAs, affected
regulatory networks are likely to be modiﬁed by countless miRNA
contributors and will continue to evolve.
Many questions arise when comparingmiRNA expression pro-
ﬁles in different model systems in vitro and in vivo and when
comparing miRNA expression proﬁles in H. pylori-infected gas-
tric tissue and gastric cancer. For example, miR-106b, a known
oncogenic miRNA, upregulated in variousmalignancies including
gastric cancer, is decreased in H. pylori-infected gastric mucosa.
Similarly, miR-34b, miR-34c, miR-103, miR-200a, miR-200b, miR-
214, and miR-372 are all overexpressed in gastric cancer, while in
H. pylori-infected gastric mucosa these miRNAs are signiﬁcantly
downregulated. In contrast,miR-146a is signiﬁcantly decreased in
gastric cancer, but upregulated in H. pylori-infected gastric tissue.
However, a recent report has shown that miR-146a is upregulated
in a subset of gastric cancers. Although examiningmiRNA expres-
sion signatures in gastric cancer is clearly important in under-
standing the disease, development of novel therapeutics requires
greater insight into the miRNA proﬁles in precancerous gastric
tissues. Since the majority of gastric cancers arise within the con-
text of chronic inﬂammation, it will be particularly important to
discriminate between preneoplastic and tumor-speciﬁc miRNA
expression proﬁles. A more comprehensive understanding of the
roles of miRNAs in normal biological processes and disease is
needed to fully appreciate miRNA dysregulation by pathogens,
such as H. pylori. Furthermore, the relationship between single
miRNAs and their targets are important to consider, but many
of these relationships are cell and context speciﬁc. Thus, it is
critically important to dissect these intricate pathways and under-
standhowhost–pathogen interactions disrupt these encompassing
regulatory pathways.
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APPENDIX
Table A1 | miRNAs downregulated in gastric cancer.
miRNAs Target mRNAs* Biological processes targeted Reference
let-7a RAB40C Cell cycle progression Li et al. (2010, 2011c), Motoyama et al. (2008), Tsujiura et al.
(2010),Yang et al. (2011), Zhang et al. (2007), Zhu et al. (2010c)Proliferation
HMGA2 Invasion
miR-9 CDX2 Cell cycle progression Luo et al. (2009), Rotkrua et al. (2011),Tsai et al. (2011a),Wan
et al. (2010)NFκB1
GRB2, RAB34 Proliferation
miR-15b BCL2 Apoptosis Xia et al. (2008)
miR-16 BCL2 Apoptosis Shin et al. (2011), Xia et al. (2008)
miR-29a p42.3 Cell cycle progression Cui et al. (2011), Lang et al. (2010)
Proliferation
CDC42 Invasion
miR-29b CDC42 Proliferation Lang et al. (2010)
Invasion
miR-29c CDC42 Proliferation Lang et al. (2010)
Invasion
miR-30a ND ND Li et al. (2010)
miR-30b ND ND Ueda et al. (2010)
miR-30c ND ND Ueda et al. (2010)
miR-31 ND ND Guo et al. (2009), Zhang et al. (2010b)
miR-33b ND ND Volinia et al. (2006)
miR-34 BCL2 Apoptosis Ji et al. (2008)
miR-96 ND ND Volinia et al. (2006)
miR-101 COX-2, FOS Proliferation Varambally et al. (2008), Wang et al. (2010)
MCL1 Apoptosis
EZH2 Invasion migration




miR-128b ND ND Katada et al. (2009)
miR-129 CDK6 Cell cycle progression Katada et al. (2009), Shen et al. (2010), Tsai et al. (2011b),Wu
et al. (2010a)Proliferation
SOX4 Apoptosis
miR-133b ND ND Guo et al. (2009), Wu et al. (2011a)
miR-136 ND ND Ueda et al. (2010)
miR-138 ND ND Volinia et al. (2006)
miR-139-5p ND ND Guo et al. (2009)
miR-141 FGFR2 Proliferation Du et al. (2009)
miR-143 ND Proliferation Li et al. (2011a), Takagi et al. (2009), Wu et al. (2011a)
miR-145 ND ND Li et al. (2011a), Takagi et al. (2009), Tchernitsa et al. (2010)
miR-146a IRAK1,TRAF6 Immune response Hou et al. (2011), Kogo et al. (2011), Li et al. (2011a,d), Okubo
et al. (2010), Tchernitsa et al. (2010)Proliferation
Apoptosis
miR-148 ND ND Katada et al. (2009)
miR-148a CCKBR Proliferation Chen et al. (2010), Guo et al. (2011), Zheng et al. (2011)
p27 Cell cycle progression
ROCK1 Invasion and metastasis
miR-148b CCKBR Proliferation Song et al. (2011)
miR-152 CCKBR Proliferation Chen et al. (2010), Ueda et al. (2010)
(Continued)
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Table A1 | Continued
miRNAs Target mRNAs* Biological processes targeted Reference
miR-181b BCL2 Apoptosis Jiang et al. (2011), Li et al. (2011c), Zhu et al. (2010b)
miR-181c NOTCH4, KRAS Proliferation Hashimoto et al. (2010), Zhu et al. (2010b)
BCL2 Apoptosis
miR-195 ND ND Guo et al. (2009), Wu et al. (2011a)
miR-197 ND ND Li et al. (2011c)
miR-203 ABL1 Proliferation Chiang et al. (2011), Craig et al. (2011b)
Invasion
miR-210 ND ND Li et al. (2011c)
miR-212 MECP2 Proliferation Volinia et al. (2006), Wada et al. (2010), Wu et al. (2011a), Xu
et al. (2010)MYC
miR-218 ECOP Proliferation Gao et al. (2010), Tie et al. (2010), Ueda et al. (2010), Volinia
et al. (2006)Apoptosis
ROBO1 Invasion and metastasis
miR-331-3p E2F1 Cell cycle progression Guo et al. (2010)
Proliferation
miR-339 ICAM-1 Immune response Ueda et al. (2009)
miR-375 PDK1, 14-3-3 Apoptosis Ding et al. (2010), Tsukamoto et al. (2010), Ueda et al. (2010),
Xu et al. (2011)JAK2 Proliferation
miR-378 ND ND Guo et al. (2009), Yao et al. (2009)
miR-433 GRB2 Proliferation Luo et al. (2009)
miR-449 GMNN,CCNE2 Cell cycle progression Bou Kheir et al. (2011), Lize et al. (2011)
MET, SIRT1 Proliferation
miR-451 MIF Proliferation Bandres et al. (2009)
Apoptosis
miR-497 BCL2 Apoptosis Guo et al. (2009), Zhu et al. (2011b)
miR-512-5p MCL1 Apoptosis Saito et al. (2009)
miR-638 ND ND Yao et al. (2009)
miR-768-3p ND ND Guo et al. (2009)
*Target criteria included (1) reduced protein expression upon miRNA transfection in gastric cells or expression inversely correlated with miRNA in gastric tissue or (2)
presence of miRNA binding site on the 3′UTR of target mRNA conﬁrmed by luciferase reporter assay. ND, target mRNA or biological process not determined. Bold
indicates miRNA also downregulated following H. pylori infection.
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Table A2 | miRNAs upregulated in gastric cancer.
miRNAs Target mRNAs* Biological processes targeted Reference
miR-7 ND ND Volinia et al. (2006), Wu et al. (2011b)
miR-17 ND ND Guo et al. (2009),Volinia et al. (2006),Yao et al. (2009), Zhou et al. (2010)
miR-17-5p ND ND Petrocca et al. (2008), Tsujiura et al. (2010), Ueda et al. (2010), Volinia
et al. (2006)
miR-18a ND ND Guo et al. (2009), Yao et al. (2009)
miR-18b ND ND Guo et al. (2009)
miR-19a ND ND Guo et al. (2009), Ueda et al. (2010)
miR-20a ND ND Guo et al. (2009), Volinia et al. (2006)
miR-20b ND ND Guo et al. (2009), Katada et al. (2009), Ueda et al. (2010)
miR-21 PDCD4 Proliferation Chan et al. (2008), Guo et al. (2009), Li et al. (2010, 2011c), Lu et al.
(2008), Motoyama et al. (2010), Petrocca et al. (2008), Shin et al. (2011),




miR-23a IL-6R Proliferation Li et al. (2011c), Volinia et al. (2006), Zhu et al. (2010a)
Apoptosis
miR-23b ND ND Li et al. (2011c)
miR-24 AE1 Proliferation Chan et al. (2010), Volinia et al. (2006), Wu et al. (2010b)
Differentiation
miR-25 p57 Cell cycle progression Kan et al. (2009), Kim et al. (2009), Li et al. (2011c), Petrocca et al.
(2008), Ueda et al. (2010), Volinia et al. (2006)BIM Apoptosis
miR-27 APC Epithelial to mesenchymal transition (EMT) Zhang et al. (2011)
miR-27a PHB Proliferation Katada et al. (2009), Li et al. (2011a); Liu et al. (2009), Sun et al. (2010),
Zhao et al. (2011)ZBTB10 Metastasis
miR-34a SIRT1 Cell cycle progression Craig et al. (2011a),Yamakuchi and Lowenstein (2009),Yao et al. (2009)
FOXP1 Proliferation
miR-34b ND ND Katada et al. (2009), Suzuki et al. (2010), Tsai et al. (2011b)
miR-34c ND ND Katada et al. (2009), Suzuki et al. (2010)
miR-92 ND ND Li et al. (2011c), Petrocca et al. (2008), Ueda et al. (2010), Volinia et al.
(2006)
miR-93 p21 Cell cycle progression Kim et al. (2009), Petrocca et al. (2008), Ueda et al. (2010)
BIM Apoptosis
miR-98 ND ND Yao et al. (2009)
miR-99a ND ND Li et al. (2011c)
miR-99b ND ND Volinia et al. (2006)
miR-103 ND ND Li et al. (2011c), Tchernitsa et al. (2010), Volinia et al. (2006)
miR-106a RB1 Cell cycle progression Guo et al. (2009), Petrocca et al. (2008), Tsujiura et al. (2010), Ueda
et al. (2010), Volinia et al. (2006), Xiao et al. (2009a), Yao et al. (2009)Proliferation
miR-106b p21 Cell cycle progression Guo et al. (2009), Kim et al. (2009), Petrocca et al. (2008),Tsujiura et al.
(2010), Ueda et al. (2010), Yao et al. (2009)BIM Apoptosis
miR-107 CDK6 Proliferation Feng et al. (2011), Li et al. (2011b,c), Volinia et al. (2006)
DICER Invasion and metastasis
miR-125b ND ND Li et al. (2011c), Ueda et al. (2010), Volinia et al. (2006)
miR-128a ND ND Katada et al. (2009)
miR-130b RUNX3 Apoptosis Li et al. (2002), Lai et al. (2010), Yao et al. (2009)
miR-135a ND ND Ueda et al. (2010)
miR-138 ND ND Yao et al. (2009)
miR-146a SMAD4 Proliferation Xiao et al. (2011)
Apoptosis
miR-147 ND ND Yao et al. (2009)
miR-150 EGR2 Apoptosis Katada et al. (2009), Wu et al. (2010c)
(Continued)
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Table A2 | Continued
miRNAs Target mRNAs* Biological processes targeted Reference
miR-155 IKK-ε, SMAD2 Immune response Fassi Fehri et al. (2010), Oertli et al. (2011), Tang et al. (2010), Thai
et al. (2007), Volinia et al. (2006), Xiao et al. (2009b),Yao et al. (2011)FADD, PKIα Apoptosis
miR-181a-2 ND ND Yao et al. (2009)
miR-185 ND ND Yao et al. (2009)
miR-191 NDST1 Proliferation Li et al. (2011c), Shi et al. (2011), Ueda et al. (2010), Volinia et al.
(2006)
miR-192 ALCAM Proliferation Jin et al. (2011), Volinia et al. (2006)
miR-196a ND ND Okubo et al. (2010), Yao et al. (2009)
miR-200a ZEB1, ZEB2 Epithelial to mesenchymal transition (EMT) Ahn et al. (2011)
miR-200b ZEB1, ZEB2 EMT Ahn et al. (2011), Zhu et al. (2011a)
BCL2, XIAP Apoptosis
miR-214 ND ND Li et al. (2011c), Ueda et al. (2010), Volinia et al. (2006)
miR-215 ALCAM Proliferation Jin et al. (2011), Volinia et al. (2006)
Apoptosis
miR-221 p27, p57 Cell cycle progression Chun-Zhi et al. (2010), Kim et al. (2009), Li et al. (2011c), Volinia et al.
(2006), Yao et al. (2009)PTEN Proliferation
miR-222 p27, p57 Cell cycle progression Chun-Zhi et al. (2010), Kim et al. (2009), Li et al. (2011c), Ueda et al.
(2009), Volinia et al. (2006)PTEN Proliferation
ICAM-1 Immune response
miR-223 EPB41L3 Invasion and metastasis Li et al. (2011c), Petrocca et al. (2008), Volinia et al. (2006),Yao et al.
(2009)
miR-302f ND ND Yao et al. (2009)
miR-337-3p ND ND Yao et al. (2009)
miR-340 ND ND Guo et al. (2009), Yao et al. (2009)
miR-345 ND ND Ueda et al. (2010)
miR-372 LATS2 Cell cycle progression Cho et al. (2009)
Apoptosis
miR-421 CBX7, RBMXL1 Proliferation Guo et al. (2009), Jiang et al. (2010)
miR-520c-3p ND ND Yao et al. (2009)
miR-575 ND ND Yao et al. (2009)
miR-601 ND ND Yao et al. (2009)
miR-616 ND ND Yao et al. (2009)
miR-650 ING4 Apoptosis Zhang et al. (2010a)
miR-658 ND ND Guo et al. (2009)
miR-1259 ND ND Yao et al. (2009)
*Target criteria included (1) reduced protein expression upon miRNA transfection in gastric cells or expression inversely correlated with miRNA in gastric tissue or (2)
presence of miRNA binding site on the 3′UTR of target mRNA conﬁrmed by luciferase reporter assay. ND, target mRNA or biological process not determined. Bold
indicates miRNA also upregulated following H. pylori infection.
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